In this week’s video, Dr. Brian G.M. Durie defines minimal residual disease (MRD) and explains how MRD-testing can be used for ongoing monitoring.

BOTTOM LINE:

As it may one day be a guide for assessing treatment outcomes, myeloma patients should familiarize themselves with MRD-testing.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
Top Five Trends in Myeloma News for 2018
Next Post
What are the prospects for early diagnosis, CRISPR gene-editing, and CAR T-cell therapies in myeloma?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.